Porphyria

• Disease Description (Causes and Symptoms)

  • Definition and pathophysiology: Porphyria is a group of disorders caused by genetic or acquired deficiencies of specific enzymes involved in hemoglobin synthesis, resulting in the accumulation of porphyrins or their precursors (δ‑ALA, PBG, uroporphyrin, coproporphyrin, etc.) in cells, blood, urine, and stool. Depending on the site of accumulation and the deficient enzyme, the clinical presentation differs between acute neurovisceral types (e.g., acute intermittent porphyria, AIP) and cutaneous types (e.g., porphyria cutanea tarda, PCT; congenital erythropoietic porphyria, CEP).
  • Main causes: Genetic defects (autosomal dominant or recessive forms), and acquired triggers such as liver disease, alcohol, medications, hormonal changes, and iron overload.
  • Main symptoms
    • Acute type (neurologic and gastrointestinal): Severe abdominal pain, nausea and vomiting, constipation, muscle weakness and neuropathy, anxiety, depression, visual hallucinations, seizures, anemia, and darkening of the urine and stool (reddish discoloration). Hyponatremia and respiratory failure due to respiratory muscle weakness may occur.
    • Cutaneous type: Blisters, easy skin breakdown, and wounds or scarring easily occurring on sun-exposed areas (photosensitivity), skin fragility, scarring, hirsutism (excessive hair growth), and hyperpigmentation. The late-onset form may be accompanied by liver dysfunction and cirrhosis.
    • Other: Gum atrophy and tooth deformities (rare), hemolytic anemia, splenomegaly, etc.

• Treatment Methods (Standard Treatment, Medications, Procedures/Surgery, Lifestyle Management, and Precautions)

  • During an acute attack (neurologic and gastrointestinal symptoms)
    • Inpatient treatment: Monitoring of vital signs, electrolytes (especially Na), and respiratory function.
    • Specific treatment: Intravenous hemin (heme arginate) is the standard treatment and suppresses acute attacks. High-carbohydrate intake (intravenous or oral glucose) may help suppress mild attacks.
    • Symptomatic treatment: Strong analgesics (non-opioid and opioid pain control), antiemetics, and seizure control (use non-triggering anticonvulsants during seizures—the choice of seizure medication should be discussed with a specialist).
  • Chronic and cutaneous types (such as PCT)
    • Removal of triggers: Correct alcohol use, estrogen exposure (such as oral contraceptives), hepatotoxic medications, and iron overload.
    • Treatment: Regular phlebotomy to reduce iron in the liver and body. Low-dose chloroquine or hydroxychloroquine (following medically indicated dosages) to promote increased excretion.
    • Photosensitivity management: Ultraviolet protection, wearing protective clothing and hats, and beta-carotene (symptom relief in some patients).
  • Severe congenital types (e.g., CEP)
    • Symptom relief: Avoidance of light, transfusions (for severe hemolytic anemia), and splenectomy (in selected cases).
    • Curative treatment: Bone marrow (hematopoietic stem cell) transplantation has been reported as curative treatment in some patients (evaluation at a specialized center).
  • Lifestyle management and precautions
    • Avoid triggers (certain medications, alcohol, smoking, acute stress or infections, fasting or low-carbohydrate diets, changes in sex hormones, etc.).
    • Consider early hospitalization and hemin use during an attack.
    • Consult a specialist in advance regarding pregnancy, breastfeeding, surgery, anesthesia, etc.
    • Depending on the possibility of chronic liver complications (cirrhosis and risk of hepatocellular carcinoma), consult the treating physician about the need for regular follow-up liver function tests and imaging studies.
  • Risk of complications
    • Acute type: Persistent neurologic damage (motor weakness, respiratory failure), electrolyte abnormalities, and risk of death.
    • Cutaneous type: Repeated skin damage and infection, liver disease (iron accumulation and cirrhosis), and a reported increased risk of hepatocellular carcinoma (HCC) in some types of porphyria.
  • Medication safety
    • Many medications can worsen porphyria (particularly some anticonvulsants, barbiturates, rifampin, salicylates, and some antibiotics), so porphyria safety information should be checked before starting any new medication (confirm the specialized medication list with the treating physician or pharmacist).

• Checkpoints Before an Outpatient Visit (Including Items to Bring, Records, and Example Questions)

  • Items and materials to prepare
    • A list of all current medications and supplements (including dosage and frequency of administration).
    • Previous test results (liver function tests, blood tests, and, if possible, photographs of recent changes in urine or stool color).
    • Symptom diary: Time of symptom onset, duration, triggers (food, medications, alcohol consumption, menstruation, etc.), and symptom patterns (abdominal pain, skin lesions, neurologic symptoms).
    • Family history: Similar symptoms (abdominal pain or skin lesions) or family members who have already been diagnosed.
    • Results of previously performed porphyria-related tests (urine PBG/ALA, blood/red blood cell porphyrins, stool porphyrins, and genetic testing).
  • Items to check during an outpatient visit (example questions)
    • Have you recently started any new medications or supplements?
    • Have there recently been alcohol consumption, weight loss, fasting, stress, surgery, or pregnancy?
    • When did the urine color (darkness/redness) or skin symptoms worsen, and what is the pattern?
    • Does anyone in the family have similar symptoms or genetic testing results?
  • Tips for preparing for tests
    • Urine collection: Urine testing (PBG, ALA, etc.) during an attack or immediately after symptoms begin is useful for diagnosis. The color may become darker due to oxidation during storage.
    • For diagnosis, combined blood, urine, and stool testing along with genetic testing is recommended.

• General Example Questions to Ask the Doctor

  • What is the cause of this disease, and which type do I have (acute, cutaneous, congenital, etc.)?
  • What do my current test results mean? What additional tests do I need?
  • How should an acute attack be treated in an emergency, and when should I be hospitalized immediately?
  • Could any of the medications I am taking worsen this disease? What alternatives are available?
  • What are the management methods and risks during pregnancy and breastfeeding?
  • What is the prognosis, and how likely are long-term complications (such as liver disease or neurologic damage)?

• Examples of Disease-Specific Questions

  • (For those suspected of having the acute type) If my urine PBG/ALA levels are higher than normal, what additional tests or treatment are needed? What are the indications and side effects of hemin treatment?
  • (For patients with the cutaneous type/PCT) What tests should be performed to evaluate iron overload and liver disease, and how are the schedule and target hemoglobin/iron indicators for phlebotomy determined? Is low-dose chloroquine treatment appropriate?

Reference (Diagnostic Points)

• When acute neurovisceral porphyria is suspected: An increase in urine PBG and ALA during symptom onset is diagnostic. The type is differentiated based on blood, red blood cell porphyrin, and stool porphyrin patterns. Genetic testing is helpful for confirmation and family testing.
• When a cutaneous type is suspected: Urine, stool, and blood (red blood cell) porphyrin patterns, as well as liver function and iron-related tests, are needed.

(Diagnosis and treatment vary greatly among individual patients; specific prescriptions, medication discontinuation, and decisions about whether to undergo procedures should be made in consultation with the treating specialist.)